Healio: Wegovy Improves Exercise Function in Obesity-Related Heart Failure with Concomitant Weight Loss

Semaglutide 2.4 mg was linked to early, sustained improvement in exercise function among patients with obesity-related heart failure (HF) and improved most among those with the largest proportionate weight loss.

The results of a secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials were presented at a virtual late-breaking clinical research session of the Heart Failure Society of America Annual Scientific Meeting. 

“We know that heart failure with preserved ejection fraction now represents the majority of heart failure cases in the community, and among those with heart failure with preserved ejection fraction, the majority are also living with overweight or obesity,” Mikhail Kosiborod, MD, FACC, FAHA, said cardiologist at Saint Luke’s Mid America Heart Institute. “Previous studies have demonstrated that among patients with obesity-related HFpEF, those patients experience worse burden of symptoms, physical limitations and a greater degree of exercise impairment.

Read the full Healio article: Wegovy Improves Exercise Function in Obesity-Related Heart Failure with Concomitant Weight Loss

Related Content

Sep. 6, 2024

BBC News: Studies Reveal New Effects of Semaglutide
BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.
Sep. 6, 2024

Times Radio: Research Finds New Positive Impacts of Semaglutide
More than 10 studies presented at the European Society of Cardiology Congress revealed new findings on the far-reaching benefits of semaglutide.
Sep. 4, 2024

Healio: Semaglutide Cuts Risk for Worsening Heart Failure, CV Death Among Adults with HFpEF
Semaglutide cut the risk for worsening heart failure and cardiovascular death for adults with heart failure with preserved ejection fraction, according to new data presented by Dr. Mikhail Kosiborod.